In addition to these five FDA-approved drugs, ongoing research and development efforts are exploring additional IL-17-targeting therapies, such as Vunakizumab, Izokibep (ABY-035), and ZL1102, all of which show promising potential for psoriasis treatment. This evidence concerns the gene IL17A and psoriasis.